Generally speaking, the rationale of the present study is to design a novel anticancer therapy using bevacizumab (avastin; AV) and CCR2 inhibitor (CR)-encapsulated nanoparticles and applied them against hepatocellular carcinoma (HepG2 and Huh-7) and non-small cell lung cancer (A549) cell lines. Here, CCR2 is linked to non-small cell lung carcinoma.